Base Year
Historical Year
Forecast Year
The synovial sarcoma market size is expected to grow at a CAGR of 4% during the forecast period of 2024-2032, driven by the increasing incidence of the disease along with rising technical advances to offer targeted therapies to patients.
Synovial sarcoma, also known as soft tissue sarcoma, is a rare cancer occurring in the connective tissues of the body. It usually affects the arms, legs, and belly. Symptoms include a painless lump in the hip, knee, ankle to shoulder. A sudden sharp pain along with swelling may also persist in patients. Synovial sarcoma is mostly slow growing and can be diagnosed via imaging tests, or biopsy.
In 2023, around 13,400 new soft tissue sarcomas are expected to be diagnosed in the United States. While 5,140 deaths (2,720 males and 2,420 females) are associated with the condition. It is more prevalent in adolescents and adults younger than 30 years of age, making it the third most commonly occurring in young adults and adolescents. The survival rate is approximately 50-60% at 5 years and 40-50% at 10 years. The ongoing advancements in oncology domain and monoclonal antibodies development are expected to improve the survival rates significantly.
Development in CAR T-cell Therapies for Personalized Treatment
To beat the rising mortalities associated with the condition, the synovial sarcoma market growth has been quite significant in recent years. In December 2023, Adaptimmune Therapeutics plc , a cancer therapy leader announced the submission of its Biologics License Application (BLA) to the FDA for afami-cel. Afami-cell is an investigational T-cell therapy intended to target melanoma-associated antigen (MAGE)-A4 and mesothelin, which has been supported by the positive data from SPEARHEAD-1 trial.
Advancements in Immunotherapy to Meet Synovial Sarcoma Market Demand
Immunotherapy has been a key area of investigation amongst researchers, owing to its ability to offer customized and effective treatment to patients. An October 2023 study published in Clinical Cancer Research revealed that immunotherapy with TB-1301 that targets NY-ESO-1-positive tumor cells showcased promising outcomes against recurrent synovial sarcoma. As per researchers, the efficacy and objective response rate was significantly better against pazopanib (Votrient) and other immunotherapy regimens. This indicates that the upcoming progressions in biotechnology and gene therapy are expected to build improved therapies.
Increased Research Activities to Identify Disease Prognosis
In July 2023, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) researchers, upon the molecular analysis of the tumor identified that a BRAF V600E mutation was responsible for progression of relapsed disease. Such initiatives aimed at identifying the root cause of tumor progression at genetic level are expected to help the scientists come up with better therapeutic alternatives and lead to an increased synovial sarcoma market share in coming years.
Improvement in Existing Methods of Therapy
Over the years, medications such as doxorubicin, halaven and imatinib, along with radiotherapy have been used to shrink tumor size. This also helps in ensuring the accuracy in surgery. There have been high investments and research in developing new and effective medications, which are anticipated to increase the synovial sarcoma market size in the forecast period. Currently, Trabectedin, also known as Ecteinascidin-743 (ET-743) is administered to patients. TKI inhibitors such as Pazopanib are also considered effective.
Market Breakup by Diagnosis
Market Breakup by Type
Market Breakup by Treatment
Market Breakup by Distribution Channel
Market Breakup by End User
Market Breakup by Region
Europe, especially with a significant amount of geriatric population, holds high market value. The existence of several research and academic institutions plays a pivotal role in boosting market growth by offering novel treatments that showcase improved efficacy and reduced side effects. The increasing progression of clinical trials also impacts the market positively. The United States is anticipated to lead the synovial sarcoma market share owing to its well-equipped and technically advanced healthcare infrastructure. Several pharmaceutical companies are collaborating with advanced start-ups to leverage the latest techniques and devise quality treatment options to address the unmet needs of patients suffering from the disease.
The Asia Pacific, led by Japan is projected to experience a significant upswing in the synovial sarcoma market value. The growth can be credited to increasing healthcare investment in the region. Governments and organisations are also working on raising awareness via campaigns and programs to help the masses assess the early signs of the condition.
In November 2023, a clinical stage biotechnology firm Intensity Therapeutics, Inc . revealed that their lead proprietary investigational product candidate called INT230-6, alone or in combination with ipilimumab, was safe, tolerable, and effective in treating patients with relapsed, refractory, and metastatic sarcomas. The company using latest technologies such as the DfuseRxâ„ technology platform. This also indicates the trend of prominent companies deploying novel technologies to develop effective solutions for patients.
The key features of the synovial sarcoma market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnosis |
|
| Breakup by Type |
|
| Breakup by Treatment |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is anticipated to grow at a CAGR of 4% during the forecast period of 2024-2032, driven by the increasing incidence of the disease, along with increasing technical advances to provide targeted therapies to patients.
The market demand is driven by increasing awareness of the disease among the public which has fuelled the frequency of clinical trials and drug approvals in recent times.
The current market trend is majorly around growing developments in gene therapy and combination therapies. A Clinical Cancer Research study published in October 2023 revealed that TB-1301 targets NY-ESO-1-positive tumor cells demonstrated positive results against pazopanib (Votrient) and other immunotherapy regimens.
Based on product types, the market is divided into ACXT-3102, AL-3818, Axitinib, CMB-305, and CUE-102, among others.
Major end users include hospitals and clinics.
Surgery, anti-angiogenesis, drugs, radiation therapy, and chemotherapy are common treatments available in the market.
Imaging, biopsy and others are common types of diagnosis.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are F. Hoffmann-La Roche Ltd., Bayer AG, Epizyme, Bionpharma Cue Biopharma, Adaptimmune Therapeutics Plc, Advenchen Laboratories LLC, EpiZyme Inc., Merck & Co., Immunocore Ltd., Johnson & Johnson Private Limited., Karyopharm Therapeutics Inc., Novartis AG, Pfizer Inc., Takara Bio Inc., and Eli Lilly and Company.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Subscribe to our Newsletter
By subscribing you agree to with our privacy policy and provide
consent to
receive
updates
from our company.
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
Share